The broad goal of the OIB Program is to develop and assess quantitative systems and technologies thatimprove detection, clinical management, and quality of life for cancer patients. OIB is strongly interdisciplinary,integrating basic scientists with technologists and clinicians and is focused around 3 key themes. Critically,each of the themes includes basic science, technology development, and translational research activitiesspanning from animal models to human subjects in various types of cancers, including breast, skin, GI, oralcavity, prostate, and brain. We also apply emerging technologies in multi-center and cooperative group clinicaltrials in order to standardize and validate methods and endpoints for improved cancer detection and clinicalmanagement. The three themes are: 1) Cancer imaging and treatment using Biophotonics and BiomedicalOptics technologies, including a broad range of non-linear optical microscopies, Laser Microbeams, OpticalCoherence Tomography, Acousto-Optic Imaging and Elastography, Laser Speckle Imaging, Spatial FrequencyDomain Imaging, and Diffuse Optical Spectroscopy and Imaging; 2) Cancer imaging and treatment using MRI,Nuclear, X-Ray/CT, multi-Modality technologies; and 3) Cancer detection and therapy using molecular, cellular,and material technologies, from nano- and microfluidic platforms and integrated ?lab-on-a-chip? and ?body-ona-chip? systems, to advanced cellular and molecular diagnostics for improved cancer detection and therapy.Importantly, the new technologies and methods for engineering cellular systems we are developing areoptimized such that their integration into multi-system platforms allows visualization using many of thetechnologies developed in themes 1 and 2. OIB leadership works to leverage these technologies to improvecancer detection, clinical management and patient quality of life through three Specific Aims: 1) Develop noveltools for cancer detection and treatment; 2) Foster multi-disciplinary collaborations to validate these tools inpreclinical cancer models; and, 3) Validate novel technologies in multi-center and cooperative group clinicaltrials.Membership: 28 Members from 15 DepartmentsFunding: $3,516,292 NCI (Totals); $5,218,874 Other Peer-Reviewed (Totals)Publications: 347 Publications, 11% Inter-programmatic; 22% Intra-programmatic
Showing the most recent 10 out of 1106 publications
